CagriSema achieves significant weight loss in diabetes patients

CagriSema has shown nearly 16% weight loss in adults with obesity and type 2 diabetes in the Phase 3 REDEFINE 2 trial, surpassing placebo results. Lorundrostat has demonstrated significant blood pressure reduction in patients with uncontrolled hypertension in recent Phase 3 and Phase 2 trials, maintaining a favorable safety profile. The FDA has set a new Priority Review date of June 4, 2025, for PharmaTher's ketamine treatment. Additionally, ATSN-201 gene therapy received Fast Track designation for X-linked retinoschisis, and the FDA approved the first interchangeable biosimilar for omalizumab.